A panel of U.S. health advisers has recommended the U.S. Food and Drug Administration authorize a second shot of Johnson & Johnson’s COVID-19 vaccine for anyone who has received the single-dose inoculation.
The panel expressed concerns Friday that Americans who received the shot are not as protected as those who were given a two-dose vaccination from drugmakers Pfizer or Moderna.
Last month, the FDA authorized a third booster shot for the Pfizer vaccine for seniors as well as adults who are at high risk for COVID-19. On Thursday, the FDA advisory panel recommended a similar course of action for Moderna boosters, except using lower doses.
Johnson & Johnson is the only COVID-19 vaccine approved in the United States that is only one dose. Initially, it was hailed for its ability to take effect quickly, but soon ran into concerns that it led to a rare blood clot disorder and a neurological disease called Guillain-Barre syndrome. It is now facing criticism that it is less effective than rival brands.
Only about 15 million Americans received the Johnson & Johnson vaccine out of 188 million Americans who are fully vaccinated.
In other developments Friday, the U.S. Centers for Disease Control and Prevention said it would accept mixed-dose coronavirus vaccines from international travelers. It has said it would allow travelers to have received any vaccine authorized for use by the FDA or the World Health Organization.
Earlier in the day, the White House said it would lift COVID-19 travel restrictions for international travelers who are fully vaccinated on Nov. 8.
In France, health officials ended a policy Friday of allowing free COVID-19 tests for everyone in an effort to persuade people to get vaccinated. Now, only those who have been vaccinated, who have a prescription from a doctor, or minors will be allowed to take free tests while others will have to pay.
Health ministry data Friday showed COVID-19 cases are on the rise in the country, with 6,099 new cases up from last Friday’s 4,470 cases.
South Africa said Friday it would start vaccinating children between the ages of 12 and 17 next week using the Pfizer-BioNTech vaccine. The government is trying to meet a goal of vaccinating 70% of the adult population by December.
Pfizer and its partner BioNTech said Friday they have submitted data to the European Union’s regulatory agency to approve their coronavirus vaccine for children ages 5-11. The companies have already taken a similar step with U.S. regulators.
In Italy, officials made health passes mandatory for all workers Friday. The passes must show proof of vaccination, a negative test or recent recovery from infection in order to work.
Scattered demonstrations were held across the country to protest the new rules, including 6,000 protesters in the northeastern port of Trieste.
And in Russia, the coronavirus task force said the daily number of new coronavirus infections and deaths surged to another record Friday. It reported 32,196 new confirmed coronavirus cases and 999 deaths in the previous 24 hours.